@article{91cb19ade29c475db5c5e233e99228f1,
title = "Identification of trypsin-degrading commensals in the large intestine",
abstract = "Increased levels of proteases, such as trypsin, in the distal intestine have been implicated in intestinal pathological conditions1–3. However, the players and mechanisms that underlie protease regulation in the intestinal lumen have remained unclear. Here we show that Paraprevotella strains isolated from the faecal microbiome of healthy human donors are potent trypsin-degrading commensals. Mechanistically, Paraprevotella recruit trypsin to the bacterial surface through type IX secretion system-dependent polysaccharide-anchoring proteins to promote trypsin autolysis. Paraprevotella colonization protects IgA from trypsin degradation and enhances the effectiveness of oral vaccines against Citrobacter rodentium. Moreover, Paraprevotella colonization inhibits lethal infection with murine hepatitis virus-2, a mouse coronavirus that is dependent on trypsin and trypsin-like proteases for entry into host cells4,5. Consistently, carriage of putative genes involved in trypsin degradation in the gut microbiome was associated with reduced severity of diarrhoea in patients with SARS-CoV-2 infection. Thus, trypsin-degrading commensal colonization may contribute to the maintenance of intestinal homeostasis and protection from pathogen infection.",
author = "Youxian Li and Eiichiro Watanabe and Yusuke Kawashima and Plichta, {Damian R.} and Zhujun Wang and Makoto Ujike and Ang, {Qi Yan} and Runrun Wu and Munehiro Furuichi and Kozue Takeshita and Koji Yoshida and Keita Nishiyama and Kearney, {Sean M.} and Wataru Suda and Masahira Hattori and Satoshi Sasajima and Takahiro Matsunaga and Xiaoxi Zhang and Kazuto Watanabe and Jun Fujishiro and Norman, {Jason M.} and Bernat Olle and Shutoku Matsuyama and Ho Namkoong and Yoshifumi Uwamino and Makoto Ishii and Koichi Fukunaga and Naoki Hasegawa and Osamu Ohara and Xavier, {Ramnik J.} and Koji Atarashi and Kenya Honda",
note = "Funding Information: We thank P. D. Burrows for comments; S. Narushima, T. Tanoue, T. Tanaka, S. Saegusa, M. Takekawa and M. Kumamoto for technical support and advice; H. Iseki and T. Matsui for coordinating and performing transmission electron microscopy experiments; and all of the staff members who supported us in the Keio University Hospital clinical COVID-19 Team, Keio Donner Project Team and the Japan COVID-19 Task Force. K.H. is funded through Japan Agency for Medical Research and Development (AMED) Project {\textquoteleft}The next-generation drug discovery and development technology on regulating intestinal microbiome (NeDD Trim){\textquoteright} (JP21ae0121041), AMED COVID-19-related R&D project under grant number JP20he0622002, AMED LEAP under grant number JP20gm0010003, Grant-in-Aid for Specially Promoted Research from JSPS (no. 20H05627) and Stand Up To Cancer (SU2C) Convergence 3.1416 Grant. D.R.P. and R.J.X. were funded by Center for the Study of Inflammatory Bowel Disease (DK043351) and AT009708. Y.L. received funding from RIKEN{\textquoteright}s SPDR programme and the European Union{\textquoteright}s Horizon 2020 Research and Innovation programme under the Marie Sk{\l}odowska-Curie Actions Grant, agreement no. 80113 (Scientia Fellowship). This study was also supported by AMED grants JP20fk0108452, JP20fk0108415, JP20nk0101612 and JP20ek0210154. E.W. acknowledges support from RIKEN{\textquoteright}s JRA programme. Funding Information: We thank P. D. Burrows for comments; S. Narushima, T. Tanoue, T. Tanaka, S. Saegusa, M. Takekawa and M. Kumamoto for technical support and advice; H. Iseki and T. Matsui for coordinating and performing transmission electron microscopy experiments; and all of the staff members who supported us in the Keio University Hospital clinical COVID-19 Team, Keio Donner Project Team and the Japan COVID-19 Task Force. K.H. is funded through Japan Agency for Medical Research and Development (AMED) Project {\textquoteleft}The next-generation drug discovery and development technology on regulating intestinal microbiome (NeDD Trim){\textquoteright} (JP21ae0121041), AMED COVID-19-related R&D project under grant number JP20he0622002, AMED LEAP under grant number JP20gm0010003, Grant-in-Aid for Specially Promoted Research from JSPS (no. 20H05627) and Stand Up To Cancer (SU2C) Convergence 3.1416 Grant. D.R.P. and R.J.X. were funded by Center for the Study of Inflammatory Bowel Disease (DK043351) and AT009708. Y.L. received funding from RIKEN{\textquoteright}s SPDR programme and the European Union{\textquoteright}s Horizon 2020 Research and Innovation programme under the Marie Sk{\l}odowska-Curie Actions Grant, agreement no. 80113 (Scientia Fellowship). This study was also supported by AMED grants JP20fk0108452, JP20fk0108415, JP20nk0101612 and JP20ek0210154. E.W. acknowledges support from RIKEN{\textquoteright}s JRA programme. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1038/s41586-022-05181-3",
language = "English",
journal = "Nature Cell Biology",
issn = "1465-7392",
publisher = "Nature Publishing Group",
}